Have a feature idea you'd love to see implemented?
Let us know!
AGEN Agenus Inc
Price (delayed)
$4.65
Market cap
$100.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$11.16
Enterprise value
$78.09M
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the
Highlights
The gross profit has soared by 79% YoY
Agenus's revenue has soared by 61% YoY
The quick ratio has soared by 67% from the previous quarter but it has plunged by 55% YoY
AGEN's equity has shrunk by 159% YoY and by 20% QoQ
Key stats
What are the main financial stats of AGEN
Market
Valuations
Earnings
Shares outstanding
21.57M
Market cap
$100.31M
Enterprise value
$78.09M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.49
Revenue
$159.63M
EBIT
-$99.43M
EBITDA
-$84.64M
Free cash flow
-$183.16M
Per share
Balance sheet
Liquidity
EPS
-$11.16
Free cash flow per share
-$8.7
Book value per share
-$11.49
Revenue per share
$7.58
TBVPS
$12.51
Total assets
$292.42M
Total liabilities
$513.25M
Debt
$71.51M
Equity
-$241.31M
Working capital
-$170.66M
Debt to equity
-0.3
Current ratio
0.37
Quick ratio
0.35
Net debt/EBITDA
0.26
Margins
Efficiency
Dividend
EBITDA margin
-53%
Gross margin
99.5%
Net margin
-140%
Operating margin
-71.3%
Return on assets
-74.7%
Return on equity
N/A
Return on invested capital
-504.6%
Return on capital employed
-457.2%
Return on sales
-62.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AGEN stock price
How has the Agenus stock price performed over time
Intraday
2.2%
1 week
-4.12%
1 month
-9.36%
1 year
-76.98%
YTD
-71.92%
QTD
-15.15%
Financial performance
How have Agenus's revenue and profit performed over time
Revenue
$159.63M
Gross profit
$158.84M
Operating income
-$113.78M
Net income
-$223.46M
Gross margin
99.5%
Net margin
-140%
The gross profit has soared by 79% YoY
AGEN's operating margin has soared by 66% YoY and by 17% from the previous quarter
Agenus's revenue has soared by 61% YoY
Agenus's net margin has increased by 47% YoY and by 6% QoQ
Growth
What is Agenus's growth rate over time
Valuation
What is Agenus stock price valuation
P/E
N/A
P/B
N/A
P/S
0.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.49
The EPS is up by 34% year-on-year and by 11% since the previous quarter
AGEN's equity has shrunk by 159% YoY and by 20% QoQ
The stock's price to sales (P/S) is 88% less than its 5-year quarterly average of 5.1 and 76% less than its last 4 quarters average of 2.5
Agenus's revenue has soared by 61% YoY
Efficiency
How efficient is Agenus business performance
Agenus's ROIC has plunged by 144% YoY and by 89% from the previous quarter
The return on sales has surged by 68% year-on-year and by 22% since the previous quarter
Agenus's return on assets has decreased by 17% YoY
Dividends
What is AGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AGEN.
Financial health
How did Agenus financials performed over time
AGEN's total assets is 43% lower than its total liabilities
The quick ratio has soared by 67% from the previous quarter but it has plunged by 55% YoY
Agenus's current ratio has shrunk by 56% YoY but it has surged by 54% QoQ
Agenus's debt is 130% higher than its equity
AGEN's equity has shrunk by 159% YoY and by 20% QoQ
The debt to equity has surged by 64% year-on-year and by 23% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.